Story perspectives

Medicare Pauses Weight-Loss Drug Coverage Amid Health Concerns

4/8/2025

42 10

Summary

Story summary

The Centers for Medicare and Medicaid Services paused a proposal to cover weight-loss drugs for 7.5 million beneficiaries.
Experts caution that lack of coverage could increase long-term health costs despite the drugs' benefits for heart disease.
Rising GLP-1 use among type 1 diabetes patients raises concerns about potential side effects.
Research suggests GLP-1 drugs may reduce dementia risk in type 2 diabetes patients, warranting further clinical trials.

1 of 1

Story summary

The Centers for Medicare and Medicaid Services paused a proposal to cover weight-loss drugs for 7.5 million beneficiaries.
Experts caution that lack of coverage could increase long-term health costs despite the drugs' benefits for heart disease.
Rising GLP-1 use among type 1 diabetes patients raises concerns about potential side effects.
Research suggests GLP-1 drugs may reduce dementia risk in type 2 diabetes patients, warranting further clinical trials.